Biogency Synext Tablets

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

nicotinamide, Quantity: 40 mg; pyridoxine hydrochloride, Quantity: 610 microgram (Equivalent: pyridoxine, Qty 500 microgram); Biotin, Quantity: 1 mg; cyanocobalamin, Quantity: 10 microgram; folic acid, Quantity: 150 microgram; ubidecarenone, Quantity: 50 mg; leucine, Quantity: 100 mg; heavy magnesium oxide, Quantity: 50 mg (Equivalent: magnesium, Qty 30 mg); nicotinic acid, Quantity: 100 mg; Curcuma longa, Quantity: 200 mg (Equivalent: Curcuma longa, Qty 4 g); chromium picolinate, Quantity: 64.4 microgram (Equivalent: chromium, Qty 8 microgram); riboflavin, Quantity: 1 mg; quercetin, Quantity: 200 mg; Piper nigrum, Quantity: 6 mg (Equivalent: Piper nigrum, Qty 300 mg); Reynoutria japonica, Quantity: 60 mg (Equivalent: Reynoutria japonica, Qty 6 g)

Available from:

Biogency Pty Ltd

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: maltodextrin; microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; crospovidone; povidone; silicon dioxide; magnesium stearate; purified water; Carnauba Wax; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin

Administration route:

Oral

Therapeutic indications:

Maintain/support energy production ; Anti-inflammatory/relieve inflammation ; Maintain/support cardiovascular system health ; Maintain/support healthy cardiovascular system function ; Maintain/support blood capillary health ; Maintain/support (state vitamin/mineral/nutrient) levels in the body

Product summary:

Visual Identification: ;

Authorization status:

Listed

Authorization date:

2020-02-06